Severe Psoriasis – Market Access and Reimbursement Insights Report – 2025

Severe Psoriasis Market Access and Reimbursement Insights

Thelansis’s “Severe Psoriasis Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.

Severe Psoriasis Overview

Severe psoriasis is a serious, long-term health condition characterized by an overactive immune system that mistakenly attacks the skin. Instead of allowing skin cells to renew themselves gradually, the immune signals cause them to reproduce too rapidly, leading to thick, red, itchy patches known as plaques that cover large areas of the body (typically more than 10% of the skin surface). This condition is not merely a skin issue; the same inflammation that affects the skin can spread throughout the body, resulting in other serious complications, such as painful joint damage known as psoriatic arthritis and an increased risk of heart problems. Due to its widespread impact and the significant daily pain and discomfort it causes, severe psoriasis requires strong, advanced treatments. These treatments often include specialized medications called biologics, which help calm the immune system and bring the disease under control.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* and interviews with payers (e.g., pharmacy directors / medical directors from managed care organizations with Medicare and/or Commercial plans in the United States). If required, primary market research with physicians is also done to understand the impact of reimbursement environment on treatment decisions for current and emerging brands.

*Survey and interview discussion guide are customized based on client requirements

Deliverables format:

• PowerPoint presentation

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Key business questions answered:

• Market access and reimbursement for current therapies
• Coverage on plans
• Market access restrictions
• Rebates and contracting
• Factors influencing formulary access
• HEOR requirements and influence, etc.
• Expected market access and reimbursement for key emerging therapies
• Level of awareness
• Anticipated coverage on plans
• Factors that would improve market access
• Pricing, etc.
• Impact on brand use
• Key factors driving and limiting brand use
• Best and worst performers on market access, etc.
• Evolving environment
• Payer expectations from emerging therapies
• New policies and their expected impact, etc.
• Advise to drug manufacturers and developers

Read more: Severe Psoriasis – Market Access and Reimbursement Insights Report – 2025